je.st
news
Tag: announce collaboration
IntelliCyt And FIMM Announce A Collaboration To Advance Personalized Medicine In Cancer Treatment
2016-03-02 05:45:22| drugdiscoveryonline Home Page
IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research today announced a collaboration with the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki to further the development of personalized medicine in cancer treatment
Tags: treatment
medicine
advance
cancer
AGTC and Synpromics Limited Announce R&D Collaboration to Develop...
2015-12-09 20:22:56| Biotech - Topix.net
GAINESVILLE, Fla., CAMBRIDGE, Mass. and EDINBURGH, Scotland, Dec. 9, 2015 -- Applied Genetic Technologies Corporation , a biotechnology company conducting human clinical trials of adeno-associated virus -based gene therapies for the treatment of rare eye diseases, and Synpromics Limited, a leading synthetic promoter development company backed by Calculus Capital, today announced they have entered into a broad, multi-target collaboration agreement.
Tags: to
limited
develop
collaboration
Bosch Sensortec and NextNav Announce Collaboration for Accurate Floor Level Altitude Detection
2015-11-10 11:31:12| Industrial Newsroom - All News for Today
STUTTGART, Germany and NAPA VALLEY, California, November 5, 2015 - Combination of Bosch Sensortec's digital barometric pressure sensors and NextNav MBS Network Combined technologies enable highly accurate altitude calculation MBS Network available in San Francisco Bay Area, with 47 Cellular Market Areas...
Tags: level
floor
accurate
collaboration
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
2015-10-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & HOUSTON KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and DNAtrix today announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrixs oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325Investor Relations:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879orDNAtrixInvestor/Media Relations:Imran Alibhai, Ph.D.ialibhai@dnatrix.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
2015-08-13 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & HOUSTON Clinical Trials to Evaluate Mercks KEYTRUDA (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and The University of Texas MD Anderson Cancer Center today announced that they have entered into a strategic clinical research collaboration to evaluate Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel antitumor medicines. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orMD Anderson Media Relations:Ron Gilmore, 713-745-1898Rlgilmore1@mdanderson.org Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: center
research
solid
cancer
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »